Konstantinos Sideris

Konstantinos Sideris

Auto-generated profile, based on publicly available information

Konstantinos Sideris

Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Christos P. KyriakopoulosChristos P. Kyriakopoulos
Christos P. Kyriakopoulos
Chris KapeliosChris Kapelios
Chris Kapelios
ESElizabeth L. Stauder
Elizabeth L. Stauder
ITIosif Taleb
Iosif Taleb
RHRana Hamouche
Rana Hamouche
SDStavros G. Drakos
Stavros G. Drakos
Left ventricular assist devices (LVADs) are an established treatment modality for advanced heart failure (HF). It has been shown that through volume and pressure unloading they can lead to significant functional and structural cardiac improvement, allowing LVAD support withdrawal in a subset of patients. In the first part of this review, we discuss the historical background, current evidence on the incidence and assessment of LVAD-mediated cardiac recovery, and out-comes including quality of life after LVAD support withdrawal. In the second part, we discuss current and future opportunities to promote LVAD-mediated reverse remodeling and improve our pathophysiological understanding of HF and recovery for the benefit of the greater HF population.

5 May 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
PKPaul J. Kim
Paul J. Kim
MOMichael Olympios
Michael Olympios
KSKonstantinos Sideris
Konstantinos Sideris
ETEleni Tseliou
Eleni Tseliou
TTTaylor Y. Tran
Taylor Y. Tran
JSJosef Stehlik
Josef Stehlik
Donor-derived cell-free DNA (dd-cfDNA) is a promising biomarker of acute rejection (AR) after heart transplantation (HTx). dd-cfDNA measured as a fraction of total cfDNA can be affected by changes in total cfDNA whereas dd-cfDNA quantity can mitigate this impact. This study investigates the performance of a two-threshold algorithm (2TA) that combines dd-cfDNA fraction (dd-cfDNA%) and donor-quantity score (DQS). A total of 808 plasma samples were prospectively collected for dd-cfDNA testing from 187 adult HTx patients with contemporaneous endomyocardial biopsies. cfDNA was analyzed by a single nucleotide polymorphism (SNP)-based next-generation sequencing workflow; dd-cfDNA% and DQS were measured using the sequencing reads and SNP genotypes. Both dd-cfDNA% and DQS were significantly higher in AR compared to non-AR samples (p<10-14). Considering samples exceeding either dd-cfDNA%=0.26% or DQS=18 cp/mL as positive, the 2TA demonstrated 86.5% sensitivity and 83.6% specificity for AR detection and an AUC of 0.881. Compared to dd-cfdNA% alone, performance improved with a mean net reclassification index (NRI) of 16.4% (SD: 4.0%; p=0.015) and a 37.3% reduction of the false positive rate compared to the previously established cutoff of 0.15%. Combining dd-cfDNA fraction and quantity estimate in a 2TA may improve AR detection accuracy in HTx recipients compared to dd-cfDNA% alone.

11 February 2024 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
KSKonstantinos Sideris
Konstantinos Sideris
CWCharlene R Weir
Charlene R Weir
CSCarsten Schmalfuss
Carsten Schmalfuss
HHHeather Hanson
Heather Hanson
MPMatt Pipke
Matt Pipke
JSJosef Stehlik
Josef Stehlik
Objectives: We conducted an implementation planning process during the pilot phase of a pragmatic trial, which tests an intervention guided by artificial intelligence (AI) analytics sourced from noninvasive monitoring data in heart failure patients (LINK-HF2).Materials and methods: A mixed-method analysis was conducted at 2 pilot sites. Interviews were conducted with 12 of 27 enrolled patients and with 13 participating clinicians. iPARIHS constructs were used for interview construction to identify workflow, communication patterns, and clinician’s beliefs. Interviews were transcribed and analyzed using inductive coding protocols to identify key themes. Behavioral response data from the AI-generated notifications were collected.Results: Clinicians responded to notifications within 24 hours in 95% of instances, with 26.7% resulting in clinical action. Four implementation themes emerged: (1) High anticipatory expectations for reliable patient communications, reduced patient burden, and less proactive provider monitoring. (2) The AI notifications required a differential and tailored balance of trust and action advice related to role. (3) Clinic experience with other home-based programs influenced utilization. (4) Responding to notifications involved significant effort, including electronic health record (EHR) review, patient contact, and consultation with other clinicians.Discussion: Clinician’s use of AI data is a function of beliefs regarding the trustworthiness and usefulness of the data, the degree of autonomy in professional roles, and the cognitive effort involved.Conclusion: The implementation planning analysis guided development of strategies that addressed communication technology, patient education, and EHR integration to reduce clinician and patient burden in the subsequent main randomized phase of the trial. Our results provide important insights into the unique implications of implementing AI analytics into clinical workflow.

1 September 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
Christos P. KyriakopoulosChristos P. Kyriakopoulos
Christos P. Kyriakopoulos
KSKonstantinos Sideris
Konstantinos Sideris
ITIosif Taleb
Iosif Taleb
EMEleni Maneta
Eleni Maneta
RHRana Hamouche
Rana Hamouche
SDStavros G. Drakos
Stavros G. Drakos
BACKGROUND: Cardiogenic shock (CS) can stem from multiple causes and portends poor prognosis. Prior studies have focused on acute myocardial infarction-CS; however, acute decompensated heart failure (ADHF)-CS accounts for most cases. We studied patients suffering ADHF-CS to identify clinical factors, early in their trajectory, associated with a higher probability of successful outcomes. METHODS: Consecutive patients with CS were evaluated (N=1162). We studied patients who developed ADHF-CS at our hospital (N=562). Primary end point was native heart survival (NHS), defined as survival to discharge without receiving advanced HF therapies. Secondary end points were adverse events, survival, major cardiac interventions, and hospital readmissions within 1 year following index hospitalization discharge. Association of clinical data with NHS was analyzed using logistic regression. RESULTS: Overall, 357 (63.5%) patients achieved NHS, 165 (29.2%) died, and 41 (7.3%) were discharged post advanced HF therapies. Of 398 discharged patients (70.8%), 303 (53.9%) were alive at 1 year. Patients with NHS less commonly suffered cardiac arrest, underwent intubation or pulmonary artery catheter placement, or received temporary mechanical circulatory support, had better hemodynamic and echocardiographic profiles, and had a lower vasoactive-inotropic score at shock onset. Bleeding, hemorrhagic stroke, hemolysis in patients with mechanical circulatory support, and acute kidney injury requiring renal replacement therapy were less common compared with patients who died or received advanced HF therapies. After multivariable adjustments, clinical variables associated with NHS likelihood included younger age, history of systemic hypertension, absence of cardiac arrest or acute kidney injury requiring renal replacement therapy, lower pulmonary capillary wedge pressure and vasoactive-inotropic score, and higher tricuspid annular plane systolic excursion at shock onset (all P <0.05). CONCLUSIONS: By studying contemporary patients with ADHF-CS, we identified clinical factors that can inform clinical management and provide future research targets. Right ventricular function, renal function, pulmonary artery catheter placement, and type and timing of temporary mechanical circulatory support warrant further investigation to improve outcomes of this devastating condition.

1 November 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
ITIosif Taleb
Iosif Taleb
TGTheodoros V. Giannouchos
Theodoros V. Giannouchos
Christos P. KyriakopoulosChristos P. Kyriakopoulos
Christos P. Kyriakopoulos
ACAntoine Clawson
Antoine Clawson
EDErin S. Davis
Erin S. Davis
SDStavros G. Drakos
Stavros G. Drakos
BACKGROUND: Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study’s objective was to compare costs between patients treated with and without a Shock Team and determine if the team’s implementation is cost-effective compared with standard of care. METHODS: We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018. Real-world hospital data were used to compare costs and outcomes, including survival at discharge, 1-year survival, and quality-adjusted life years gained at 1 year. Incremental cost-effectiveness ratios were calculated over a 1-year time horizon, with parameter uncertainty evaluated through probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations. RESULTS: The study involved 244 patients, with 123 treated by the Shock Team and 121 receiving standard of care. Patients were predominantly male (77.5%), with a mean age of 58 (18–92) years. The Shock Team approach improved survival rates at hospital discharge and 1-year follow-up (61.0% versus 47.9%; P =0.04 and 55.0% versus 40.5%; P =0.03, respectively). The incremental cost-effectiveness ratio for increases in survival probability at discharge for the multidisciplinary Shock Team compared with standard of care was $102 088. The incremental cost-effectiveness ratio for increases in survival probability at 1-year was estimated at $96 152 and at $127 862 per 1 quality-adjusted life year gained. Probabilistic sensitivity analysis estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150 000, while it was also dominant in almost one-third of the simulations. CONCLUSIONS: The Shock Team approach for treating refractory cardiogenic shock may be a cost-effective alternative to traditional standard of care. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.

18 February 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
Christos P. KyriakopoulosChristos P. Kyriakopoulos
Christos P. Kyriakopoulos
ITIosif Taleb
Iosif Taleb
KSKonstantinos Sideris
Konstantinos Sideris
EMEleni Maneta
Eleni Maneta
RHRana Hamouche
Rana Hamouche
SDStavros G. Drakos
Stavros G. Drakos
Background: Multidisciplinary teams and regionalized care systems have been suggested to improve cardiogenic shock (CS) outcomes. We sought to identify clinical factors associated with successful outcomes for patients developing CS at an outside healthcare facility (spoke) and being transferred to a quaternary medical center (hub). Methods and Results: Consecutive patients with CS were evaluated (N=1162). Our study cohort comprised 412 patients developing CS at a spoke. Our primary end point was native heart survival (NHS) defined as survival to discharge without receiving advanced heart failure therapies. Secondary end points were survival to discharge, 30‐day and 1‐year survival after discharge, and adverse events. Association of clinical data with NHS was analyzed using logistic regression. Overall, 246 (59.7%) patients achieved NHS, 125 (30.3%) died, and 41 (10.0%) were discharged after advanced heart failure therapies. Of the 287 patients who were discharged (69.7%), 276 (67.0%) were alive at 30 days, and 250 (60.7%) at 1 year. Patients with NHS less commonly had bleeding or vascular complications or acute kidney injury requiring renal replacement therapy compared with patients who died or received advanced heart failure therapies. Significant multivariable factors associated with NHS likelihood included younger age; shorter length of stay and transfer from a secondary compared with a tertiary/quaternary level of care spoke; absence of cardiac arrest, intubation, or type 3 bleeding; lower vasoactive–inotropic score; higher left ventricular ejection fraction at admission to the hub; and shorter CS onset‐to‐temporary mechanical circulatory support deployment time. Conclusions: We identified clinical factors reflecting disease severity and management practices including length of stay and spoke level of care, inotrope/vasopressor utilization, and CS onset‐to‐temporary mechanical circulatory support deployment time, that might inform the management of patients developing CS at a spoke.